Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Local stocks posted a solid session on Wednesday ahead of this week’s main event on global markets later tonight — the US Fed’s latest policy decision. After plenty of forward guidance, the Fed is expected to formally announce the taper of...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,398.1 points. Four ASX shares that are climbing more than most today are listed below....

“The opening of the trial in the USA – the largest global pharmaceutical market, is a major milestone. This represents a substantial de-risking of the company's lead clinical program and is a testament to the company's expertise, commitment...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Paradigm Biopharmaceuticals (PAR) has had its investigational new drug application cleared to proceed with a phase three trial on knee osteoarthritis pain The US FDA has given Paradigm the green light for a study evaluating injectable pent...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt and is charging higher on Wednesday. At the time of writing, the biopharmaceutical company’s shares are up 30% to $2.69. Why is the Paradigm shar...

While you were watching the Melbourne Cup the ASX retreated, the RBA hinted an interest rate hike could be coming sooner than 2024, and a new IPO gained 165%. The ASX 200 closed at 7,324 points – 0.63% down from yesterday. The best sector w...

The ASX 200 rose 0.64% on the first trading day of the month. All sectors were in the green except financials – a sector dragged down by Westpac (ASX:WBC) following its results. The best sectors were consumer discretionaries, telcos and uti...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is up 1.85% at time of writing to $1.93 per share. That’s a lift of more than 5% from its low of $1.83 in early morning trade. Below, we take a look at what’s helping drive today’s...

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment The company submitted the changes to the Human Research Ethics Committee, which included the addition of a test site in...

The complete set of results, including confirmatory studies will be prepared for peer review and publishing. Paradigm has filed a patent for the treatment of ARDS with PPS.

Wall Street falls as IMF warns of inflation US stock markets fell for the third consecutive day, as the International Monetary Fund (IMF) cuts its global growth projection from 6.5% to 5.9%, and warned about inflation. The IMF told the BBC...

Paradigm Biopharmaceuticals (PAR) receives top-line results from a preclinical study investigating treatment for acute respiratory distress syndrome The study saw pentosan polysulfate sodium (PPS) administered to an influenza model of acut...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.7% to 7,393.6 points. Four ASX shares that have failed to follow the market high...

The company is confident it will soon be undertaking its phase 3 PPS clinical trial in US osteoarthritis patients.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is sinking on Monday morning. At the time of writing, the biopharmaceutical company’s shares are down 8.5% to $1.92. Why is the Paradigm share price sinking? The Paradigm share pri...

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

“We are pleased to report that preparations to commence our Phase 3 clinical trial are progressing whilst we await the US FDA’s response, expected at the end of September,” says CEO.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the move this Friday. This comes after the biopharmaceutical company provided an update in regards to its upcoming clinical trial. At the time of writing, Paradigm’s shares a...

Wall Street rallies higher Confidence has returned to US markets, following the US Fed’s policy update on Wednesday night. All three US stock market benchmarks climbed overnight, with the Dow Jones rising by 1.48%, S&P 500 by 1.21%, and...

“These critical findings provide confidence in PPS as a potential world-first CHIKV therapy,” said Dr Lara Herrero.

World Overnight SPI Overnight (Jun) 7454.00 – 17.00 – 0.23% S&P ASX 200 7527.10 – 7.80 – 0.10% S&P500 4524.09 + 1.41 0.03% Nasdaq Comp 15309.38 + 50.15 0.33% DJIA 35312.53 – 48.20 – 0.14% S&P500 VIX 16.11 – 0.37 –...

World Overnight SPI Overnight (Jun) 7444.00 – 33.00 – 0.44% S&P ASX 200 7534.90 + 30.40 0.41% S&P500 4522.68 – 6.11 – 0.13% Nasdaq Comp 15259.24 – 6.65 – 0.04% DJIA 35360.73 – 39.11 – 0.11% S&P500 VIX 16.48 + 0.29...

World Overnight SPI Overnight (Jun) 7460.00 + 17.00 0.23% S&P ASX 200 7504.50 + 16.20 0.22% S&P500 4528.79 + 19.42 0.43% Nasdaq Comp 15265.89 + 136.39 0.90% DJIA 35399.84 – 55.96 – 0.16% S&P500 VIX 16.19 – 0.20 – 1...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AFG)) - Australian Finance Group ((BGA)) - Bega Cheese ((BEX)) - BikeExchange ((DTC)) - Damstra holdings ((DDH)) - DDH1 ((GDG)) - Generation Development ((GNX)) - Genex...

“The achievements of FY21 are important in our journey as a company and help set a strong foundation for Paradigm to grow,” says interim chair and CEO.

Highlights The ASX 200 was down 3.7 points to 7,487.5 during opening trade. The market breadth is reflecting investors’ mood of booking profits on the back of global cues as 7 out of the 11 sectors are trading lower. BWX’s EBITDA for...

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Zilosul® was made available during the second quarter to physicians with SAS approval to treat patients experiencing chronic arthralgia from Ross River virus (RRV) infection.

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a decline. At the time of writing, the benchmark index is down 0.35% to 7,466.6 points. Four ASX shares that are falling more than most today are listed...

Pentosan polysulfate sodium (PPS) is currently being evaluated by Paradigm for potential registration for the treatment of osteoarthritis and other inflammatory diseases in the US and other major global markets.

ASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by 0.19%. A class action proceeding against Mayne Pharma (ASX:MYX) has been brought by Phi Finney McDonald on behalf on investors who bought MY...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is under significant pressure on Tuesday morning. At the time of writing, the biopharmaceutical company’s shares are down 14.5% to $1.90. This decline means the Paradigm share pric...

Local markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday as some major M&A activity stole the headlines. Gains were led by the tech sector, as Afterpay (ASX:APT) showed its weight by dragging th...

The armed forces could be called upon to enforce Sydney’s strict lockdown, and we might see troops on the streets as early as Monday. On the bourse, the benchmark ASX 200 has closed 0.40% lower on Friday, but was flat for the week. The mini...

Securities will remain halted until Tuesday, August 3, 2021, or when an announcement is released to the market.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.6% to 7,346.2 points. Four ASX shares that are climbing more than most are listed below. Her...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is edging higher during early morning trade. This comes after the company provided an update on its Investigational New Drug (IND) application to the US Food and Drug Administratio...

The late-stage drug development company has a mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders.

NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM. The company has found a research partner in Perth-based Linear Clinical Research. Linear operates a clinical trials facility on...

After overseeing Paradigm Biopharmaceuticals’ (ASX:PAR) rise to 14-bagger highs, Paul Rennie has joined NeuroScientific Biopharmaceuticals (ASX:NSB) as Non-executive Chairman. The appointment is a substantial win for NeuroScientific given R...

Summary The ASX 200 rebounded strongly from opening losses and reclaimed 7,400 levels. The market rally was driven by strong gains in technology, telecom, and healthcare stocks. BNPL player ZIP Co was the top performer on the ASX with...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is running higher today after the company announced key clinical trial approvals in Brazil. The Paradigm share price is currently up 5.5%, trading at $2.10. Paradigm is currently...

This will be the largest clinical trial conducted using PPS in any MPS type subjects, and will evaluate the safety and tolerability of the drug as well as its effects on mobility, urinary GAG levels, walking-related pain, quality of life an...

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.7% to 7,095.9 points. Four ASX shares that have failed to follow the market higher today are...

The company is on track to respond to questions from the US Food and Drug Administration around its Investigational New Drug application within 30 days.

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...